Literature DB >> 19434483

Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.

Anshu Marathe1, Wojciech Krzyzanski, Donald E Mager.   

Abstract

Target mediated drug disposition (TMDD) describes the phenomenon where high affinity binding of a drug to its pharmacological target (enzymes or receptors) significantly alters the pharmacokinetic profile of the drug. A rapid binding model replaces the often inestimable binding micro-constants (k (on) and k (off)) of TMDD models with the equilibrium dissociation constant (K (D)) by assuming rapid binding of the drug to its target. The purpose of this study is to examine the validity of the rapid binding assumption and the pharmacokinetic properties of this model. Temporal profiles of free drug in plasma and a non-specific distribution site, free receptor, and the pharmacodynamically relevant, drug-receptor complex obtained from the rapid binding model compared favorably with the full TMDD model for small values of the parameter epsilon, which represents the ratio of the time required for drug-receptor binding relative to the time required for drug to be cleared from the system. The effect of escalating drug doses on the temporal characteristics and the comparison between the two models has been numerically investigated. A closer match between the full and rapid binding models is observed for high doses. Analysis for very large doses (Dose/V (c)) relative to endogenous steady-state receptor concentration (R (ss)), reveals that the rapid binding model reduces to a standard two compartmental model with a plasma compartment with linear drug elimination and a peripheral compartment. Decreasing clearance with increasing dose and decreasing R (ss) indicates that for drugs exhibiting TMDD, the relative ratio of R (ss) and dose is an important determinant of the pharmacokinetic properties rather than the individual parameters alone. An analytical solution derived for clearance shows that the primary elements of the apparent clearance of the drug are the linear clearance given by k (el) V (c), the non-linear clearance due to drug-receptor complex internalization (k (int)), and the ratio of AUC values of the receptor complex to that of free drug. Overall, simulations and analytical techniques applied here provide a better understanding of the validity of the rapid binding model and provide guidelines for its application.

Mesh:

Substances:

Year:  2009        PMID: 19434483     DOI: 10.1007/s10928-009-9118-8

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  21 in total

1.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

Review 2.  Antibody pharmacokinetics and pharmacodynamics.

Authors:  Evelyn D Lobo; Ryan J Hansen; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2004-11       Impact factor: 3.534

3.  Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.

Authors:  R J Bauer; R L Dedrick; M L White; M J Murray; M R Garovoy
Journal:  J Pharmacokinet Biopharm       Date:  1999-08

4.  Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers.

Authors:  Chee M Ng; Eric Stefanich; Banmeet S Anand; Paul J Fielder; Louis Vaickus
Journal:  Pharm Res       Date:  2006-11-30       Impact factor: 4.200

5.  Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding.

Authors:  K R Lees; A W Kelman; J L Reid; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1989-10

Review 6.  Pharmacologic target-mediated drug disposition.

Authors:  G Levy
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

7.  Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys.

Authors:  Donald E Mager; Berend Neuteboom; Constantinos Efthymiopoulos; Alain Munafo; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2003-03-26       Impact factor: 4.030

8.  Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man.

Authors:  Gerhard Levy; Donald E Mager; Wing K Cheung; William J Jusko
Journal:  J Pharm Sci       Date:  2003-05       Impact factor: 3.534

9.  Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition.

Authors:  E Niclas Jonsson; Fiona Macintyre; Ian James; Michael Krams; Scott Marshall
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

10.  Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).

Authors:  Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-18       Impact factor: 2.410

View more
  11 in total

1.  Theoretical considerations of target-mediated drug disposition models: simplifications and approximations.

Authors:  Peiming Ma
Journal:  Pharm Res       Date:  2011-12-01       Impact factor: 4.200

2.  Target-mediated drug disposition model for drugs that bind to more than one target.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-29       Impact factor: 2.745

Review 3.  Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations.

Authors:  Hans Peter Grimm
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-08-30       Impact factor: 2.745

4.  Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target.

Authors:  Cuyue Tang; Thomayant Prueksaritanont
Journal:  Pharm Res       Date:  2011-05-26       Impact factor: 4.200

5.  Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations.

Authors:  Gilbert Koch; William J Jusko; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-01-10       Impact factor: 2.745

6.  Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.

Authors:  Xiaoyu Yan; Donald E Mager; Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-12-10       Impact factor: 2.745

7.  Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems.

Authors:  Jun Yang; Donald E Mager; Robert M Straubinger
Journal:  AAPS J       Date:  2009-11-10       Impact factor: 4.009

8.  Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification.

Authors:  Lambertus A Peletier; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-01       Impact factor: 2.745

9.  Investigating receptor enzyme activity using time-scale analysis.

Authors:  Tao You; Hong Yue
Journal:  IET Syst Biol       Date:  2015-12       Impact factor: 1.615

10.  A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.

Authors:  P Dua; E Hawkins; P H van der Graaf
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.